Selectivity

The selectivity of a ligand refers to its relative preference for a given target over other structurally close or functionally related targets. It is a crucial attribute for any research peptide or drug: insufficient selectivity leads to off-target effects that can mask the studied effect in research or trigger adverse effects in the clinic.

Selectivity must be distinguished from specificity. Specificity is a rather binary concept (a specific antibody recognizes its epitope and no other), whereas selectivity is quantitative and relative: a peptide is "X times more selective" for target A than for target B. In practice, selectivity is expressed as a ratio of affinities or functional potencies: Kd(target B) / Kd(target A), IC50(target B) / IC50(target A), or the pKi difference. A ratio > 100 is commonly considered sufficient for a research tool, > 1000 for a drug.

Selectivity takes different forms depending on context. Subtype selectivity (for example, a μ-opioid receptor selective agonist vs κ and δ), isoform selectivity (Akt1 vs Akt2 vs Akt3, PDE5 vs PDE4), species selectivity (human vs rodent receptor, important for translating preclinical results), compartment selectivity (a peptide unable to cross the blood-brain barrier targets only the periphery), and functional selectivity (biased agonism, preferential activation of one signaling pathway over another at the same receptor).

Evaluation methods include standardized selectivity panels: cells expressing a series of related receptors (GPCR panel, kinome panel with 300+ kinases for kinase inhibitors, nuclear receptor panel for steroid hormones), ex vivo isolated tissue tests, organoids, and animal models. Preclinical off-target evaluation programs typically include a panel of 50 to 400 targets covering receptors, transporters, enzymes, ion channels, and cytochromes P450.

Design strategies to improve selectivity are multiplying. Exploiting subtle structural differences between subtypes via crystallography or cryo-EM, anchoring the peptide on a non-conserved epitope, using conformational rigidification (cyclic peptides, staples) that penalizes adaptation to secondary sites, leveraging net charge or size to filter irrelevant interactions, and incorporating non-natural amino acids that find complementarity only on the intended target.

Rigorous pharmacological analysis requires monitoring selectivity at several levels: affinity (binding), potency (function), bias (intracellular pathways), tissue distribution, and possible active metabolites that could display a different selectivity profile than the parent compound. A peptide judged "selective" in binding may prove poorly selective at therapeutic dose if its Kd/EC50 margin is narrow or if its metabolism generates promiscuous species.